Literature DB >> 29470648

Reply to letter to editor regarding: LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer.

Marcel Cabral Cognette1, Andreza Vargas da Silva2, Roberto Dias Machado2, Eliney Ferreira Faria2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29470648     DOI： 10.1007/s00345-018-2226-6

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  8 in total

Review 1.  Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.

Authors:  J Seidenfeld; D J Samson; N Aronson; P C Albertson; A M Bayoumi; C Bennett; A Brown; A Garber; M Gere; V Hasselblad; T Wilt; K Ziegler
Journal:  Evid Rep Technol Assess (Summ)       Date:  1999-05

2.  LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer.

Authors:  Andreza Vargas; Roberto Dias Machado; Daniel Ianni Filho; Carlos Eduardo Paiva; Rodolfo Borges Dos Reis; Marcos Tobias-Machado; Eliney Ferreira Faria
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

3.  No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer.

Authors:  Peter B Østergren; Tobias Wirenfeldt Klausen; Mikkel Fode
Journal:  World J Urol       Date:  2017-02-25       Impact factor: 4.226

4.  Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Authors:  Maxine Sun; Toni K Choueiri; Ole-Petter R Hamnvik; Mark A Preston; Guillermo De Velasco; Wei Jiang; Stacy Loeb; Paul L Nguyen; Quoc-Dien Trinh
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

5.  Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.

Authors:  A M Bayoumi; A D Brown; A M Garber
Journal:  J Natl Cancer Inst       Date:  2000-11-01       Impact factor: 13.506

6.  Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.

Authors:  Noboru Hara; Tsutomu Nishiyama; Itsuhiro Takizawa; Toshihiro Saito; Yasuo Kitamura; Kota Takahashi
Journal:  Urology       Date:  2010-01-29       Impact factor: 2.649

7.  Predictors of hemoglobin decline in non-metastatic prostate cancer patients on androgen deprivation therapy: a matched cohort study.

Authors:  Narhari Timilshina; Shabbir Hussain; Henriette Breunis; Shabbir M H Alibhai
Journal:  Support Care Cancer       Date:  2010-10-16       Impact factor: 3.603

8.  Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.

Authors:  Dong-Yi Chen; Lai-Chu See; Jia-Rou Liu; Cheng-Keng Chuang; See-Tong Pang; I-Chang Hsieh; Ming-Shien Wen; Tien-Hsing Chen; Yung-Chang Lin; Chuang-Chi Liaw; Cheng-Lung Hsu; John Wen-Cheng Chang; Chang-Fu Kuo; Wen-Kuan Huang
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.